To observe the clinical efficacy of intravitreal injection of Compaq in the treatment of central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) complicated with macular edema (ME).

The clinical data of 27 patients (27 eyes) with macular edema secondary to retinal vein occlusion (RVO) diagnosed by ophthalmology in Liangxiang Hospital of Beijing Fangshan District from July 2014 to February 2017 were. The patients were divided into two groups according to the types of venous obstruction, that is, group CRVO (group A) and group BRVO (group B). There were 8 cases (8 eyes) in group A, and 19 cases (19 eyes) in group B. All patients were treated with intravitreal injection of Compaq, followed by a continuous infusion of 3 injections, with 1 injections per month. The CMT and BCVA of the two groups of patients were examined before and after the first injection, 1 week after the first injection, 1 week after the second injection, 1 week after the third injection, and 1 month after the third injection, and the results were statistically analyzed. The variance of repeated measurement data were analyzed before and after treatment in two groups at different time points in the BCVA and CMT data, the difference was statistically significant, further paired t test was used for comparison of two groups.

Before group A treatment, the CMT value was (768.50±344.93)μm, and (504.13±287.91) μm 1 month after the third injection, the difference was statistically significant (t=5.079, P<0.05). The CMT values at each time point after treatment were significantly lower than those before treatment (t=2.458, 5.366, 3.614, 5.079; P<0.05). The CMT value before treatment in group B was (650.47±317.67)μm, and (332.11±187.58)μm 1 month after the third injection, the difference was statistically significant (t=7.650, P<0.05). The CMT values at each time point after treatment were significantly lower than those before treatment (t=3.967, 5.459, 6.422, 7.650; P< 0.05). The BCVA in group A was 0.95±0.31 before treatment and 0.76±0.35 1 month after the third injection. The difference was statistically significant (t=3.416, P<0.05). There was no statistical difference of BCVA between before and 1 week after the first injection (t=1.528, P>0.05). At each time point, BCVA values were significantly improved compared with those before treatment (t=2.376, 2.553, 3.416; P<0.05). The BCVA in the B group was 0.68±0.34 before treatment and 0.40±0.18 1 month after the third injection. The difference was statistically significant (t=5.931, P<0.05); At each time point after treatment, BCVA value was significantly improved compared with before treatment (t=2.163, 3.139, 5.224, 5.931; P<0.05). There was no significant difference in BCVA value between the two groups before treatment (F=3.57, P>0.05). The two groups of patients at each time point after BCVA were observed and compared, B group was higher than that of group A, and with the increase in the number of injection, the difference is more obvious, 1 month after the third injection, the difference of BCVA between the two groups was the most significant (F=7.20, 8.28, 9.01, 12.68; P<0.05).

Intravitreal injection of Compaq is safe and effective in the treatment of secondary CRVO and BRVO with ME. and the treatment effect of BRVO is more significant than that of CRVO patients.

Intravitreal injection; Compaq; Retinal vein occlusion; Macular edema